Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 901-909

  Song, Di ^a   Wientjes, M Guillaume ^a,b   Gan, Yuebo ^a   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FLUOROURIDINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; DOGS; FEMALE; FLUOROURACIL; HUMANS; MALE; METABOLIC CLEARANCE RATE; URIDINE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0030904260     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Richie, J. P. Intravesical chemotherapy: treatment selection, techniques, and results. Urol. Clin. N. Am., 19: 521-527, 1992.
2. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
3. Holmang, S., Hedelin, H., Anderstrom, C., and Johansson, S. L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol., 153: 1823-1826, 1995.
4. Soloway, M. S. Managing superficial bladder cancer: an overview. Urology, 40: 5-10, 1992.
5. Sarosdy, M. F. Principles of intravesical chemotherapy and immunotherapy. Urol. Clin. N. Am., 19: 509-519, 1992.
6. Ozen, H. Advances in bladder cancer. Curr. Opin. Oncol., 5: 574-580, 1993.
7. Inaba, M., Mitsuhashi, J., and Ozawa, S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn. J. Cancer Res., 81: 1039-1044, 1990.
8. Link, K. H., Aigner, K. R., Peschau, K., Warthona, M., Schwemmle, K., and Danenberg, P. V. Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother. Pharmacol., 22; 58-62, 1988.
9. Chabner, B. A. Pyrimidine antagonists. In: B. A. Chabner (ed.), Pharmacologic Principles of Cancer Treatment, pp. 183-212. Philadelphia: W. B. Saunders Company, 1982.
10. Heidelberger, C., Griesbach, L., Cruz, O., Schnitzer, R. J., and Grunberg, E. Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2′-deoxyuridine on transplanted tumors. Proc. Soc. Exp. Biol. Med., 97: 470-475, 1958.
11. Heimer, R., and Sartorelli, A. C. Reductions in γ-globin mRNA levels restricted to the cytoplasm of 5-fluorouridine treated K-562 human erythroleukemia cells. Cancer Commun., 2: 45-53, 1990.
12. Wilkinson, D. S., and Pitot, H. C. Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine. J. Biol. Chem., 248: 63-68, 1973.
13. Collins, J. M. Pharmacokinetics and clinical monitoring. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 16-31. Philadelphia: W. B. Saunders, 1990.
14. Wientjes, M. G., Badalament, R. A., Wang, R. C., Hassan, F., and Au. J. L. Penetration of mitomycin C in human bladder. Cancer Res., 53: 3314-3320, 1993.
15. Wientjes, M. G., Dalton, J. T., Badalament, R. A., Drago, J. R., and Au, J. L. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res., 51: 4347-4354, 1991.
16. Wientjes, M. G., Badalament, R. A., and Au, J. L. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother. Pharmacol., 37: 539-546, 1996.
17. Wientjes, M. G., Dalton, J. T., Badalament, R. A., Dasani, B. M., Drago, J. R., and Au, J. L. A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharmacol. Res., 8: 168-173, 1991.
18. Guerrieri, A., Palmisano, F., Zambonin, P. G., De Lena, M., and Lorusso, V. Solid-phase extraction of fluoropyrimidine derivatives on a copper-modified strong cation exchanger: determination of doxifluridine, 5-fluorouracil and its main metabolites in serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr., 617: 71-77, 1993.
19. Wagner, J. G. Pharmacokinetics for the Pharmaceutical Scientist, p. 316. Lancaster: Technomic Publishing, 1993.
20. Chai, M., Wientjes, M. G., Badalament, R. A., Burgers, J. K., and Au, J. L. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J. Urol., 152: 374-378, 1994.
21. Dalton, J. T., Wientjes, M. G., Badalament, R. A., Drago, J. R., and Au, J. L. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res., 51: 5144-5152, 1991.
22. Mostofi, F. K., Sobin, L. H., and Torloni, H. Histological typing of urinary bladder tumors. In: International Histological Classification of Tumors, No. 7. Geneva: WHO, 1973.
23. Au, J. L., Wientjes, M. G., Rosol, T. J., Koolemans-Beynen, A., Goebel, E. A., and Schuller, D. E. Histocultures of patient head and neck tumors for pharmacodynamics studies. Pharmacol. Res., 10: 1493-1499, 1993.
24. Schmittgen, T. D., Au, J. L., Wientjes, M. G., Badalament, R. A., and Drago, J. R. Cultured human bladder tumors for pharmacodynamic studies. J. Urol., 145: 203-207, 1991.
25. Schmittgen, T. D., Wientjes, M. G., Badalament, R. A., and Au, J. L. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res., 51: 3849-3856, 1991.
26. Gan, Y., Wientjes, M. G., Badalament, R. A., and Au, J. L. Pharmacodynamics of doxorubicin in human bladder tumors. Clin. Cancer Res., 2: 1275-1283, 1996.
27. Wientjes, M. G., Badalament, R. A., and Au, J. L. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. Pharmacol., 32: 255-262, 1993.
28. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (aie) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
29. Connolly, K. M., Diasio, R. B., Armstrong, R. D., and Kaplan, A. M. Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. Cancer Res., 43: 2529-2535, 1983.
30. Burchenal, J. H., Currie, V. E., Dowling, M. D., Fox, J. J., and Krakoff, I. H. Experimental and clinical studies on nucleoside analogs as antitumor agents. Ann. NY Acad. Sci., 255: 202-212, 1975.
31. Holstege, A., Anukarahanonta, T., Yamamoto, M., Koch, H. K., Kattermann, R., Lesch, R., and Keppler, D. Preventive effects of 5-fluorouridine and uridine on D-galactosamine-induced liver injury. Exp. Mol. Pathol., 34: 170-182, 1981.
32. el Hag, I. A., Roos, G., Jonsson, P. E., and Stenram, U. Potentiation by dipyridamole of 5-fluorouridine antitumor activity against a rat adenocarcinoma in vivo. Anticancer Res., 10: 29-32, 1990.
33. Pausch, J., Holstege, A., Anukarahanonta, T., Keppler, D., and Gerok, W. First clinical experiences with a selective chemotherapy of hepatocellular carcinoma with 5-fluorouridine in combination with other antipyrimidines. Adv. Enzyme Regul., 24: 429-434, 1985.
34. Davies, B., and Morris, T. Physiological parameters in laboratory animals and humans. Pharmacol. Res., 10: 1093-1095, 1993.
35. Sayed, Y. M. E., and Sadee, W. The fluoropyrimidines. In: M. M. Ames, G. Powis, and J. S. Kovach (eds.), Pharmacokinetics of Anticancer Agents in Humans, pp. 209-227. New York: Elsevier Science Publishers, 1983.
36. Daher, G. C., Harris, B. E., and Diasio, R. B. Metabolism of pyrimidine analogues and their nucleosides. In: G. Powis (ed.), Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, pp. 55-94. New York: Pergamon Press, 1994.
37. el Kouni, M. H., el Kouni, M. M., and Naguib, F. N. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res., 53: 3687-3693, 1993.
38. el Kouni, M. H., Naguib, F. N., Park, K. S., Cha, S., Darnowski, J. W., and Soong, S. J. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol., 40: 2479-2485, 1990.
39. Rowland, M., and Tozer, T. N. Metabolite kinetics. In: Clinical Pharmacokinetics: Concepts and Applications, pp. 347-375. Malvern, PA: Lee & Febiger, 1989.
40. Smith, D. E., Brenner, D. E., Knutsen, C. A., Deremer, S. J., Terrio, P. A., Johnson, N. J., Stetson, P. L., and Ensminger, W. D. Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs. Drug Metab. Dispos., 21: 277-283, 1993.
41. 14C-labeled mitomycin C. J. Surg. Res., 59: 415-419, 1995.
42. Wilke, A. V., Jenkins, C., Milligan, A. J., Legendre, A., and Frazier, D. L. Effect of hyperthermia on normal tissue toxicity and on Adriamycin pharmacokinetics in dogs. Cancer Res., 51: 1680-1683, 1991.
43. Zaleskis, G., Ho, R. L., Diegelman, P., Maccubbin, D., Ujhazy, P., Mihich, E., and Ehrke, M. J. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol. Res., 6: 183-194, 1994.
44. Gao, X. S., Asaumi, J., Kawasaki, S., Nishikawa, K., Kuroda, M., Li, H., Takeda, Y., Hiraki, Y., Ihara, M., and Ohnishi, T. Effect of cepharanthin and hyperthermia on the intracellular accumulation of Adriamycin in the NIH3T3 cell lines transfected with oncogenes accompanied with pSV2neo vector. Anticancer Res., 15: 1991-1996, 1995.
45. Schmittgen, T. D., Weaver, J. M., Badalament, R. A., Wientjes, M. G., Klein, E. A., Young, D. C., and Au, J. L. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J. Urol., 152: 1632-1636, 1994.